AP2014008049A0 - Optimised subcuraneous therapeutic agents - Google Patents
Optimised subcuraneous therapeutic agentsInfo
- Publication number
- AP2014008049A0 AP2014008049A0 AP2014008049A AP2014008049A AP2014008049A0 AP 2014008049 A0 AP2014008049 A0 AP 2014008049A0 AP 2014008049 A AP2014008049 A AP 2014008049A AP 2014008049 A AP2014008049 A AP 2014008049A AP 2014008049 A0 AP2014008049 A0 AP 2014008049A0
- Authority
- AP
- ARIPO
- Prior art keywords
- subcuraneous
- optimised
- therapeutic agents
- therapeutic
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1206628.8A GB201206628D0 (en) | 2012-04-16 | 2012-04-16 | Subcutaneous administration of PEGylated blood clotting factors |
GBGB1213712.1A GB201213712D0 (en) | 2012-08-01 | 2012-08-01 | Modified therapeutic agents |
GBGB1214985.2A GB201214985D0 (en) | 2012-08-22 | 2012-08-22 | Modified therapeutic agents |
PCT/EP2013/057928 WO2013156488A2 (en) | 2012-04-16 | 2013-04-16 | Optimised subcutaneous therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2014008049A0 true AP2014008049A0 (en) | 2014-11-30 |
Family
ID=48190923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2014008049A AP2014008049A0 (en) | 2012-04-16 | 2013-04-16 | Optimised subcuraneous therapeutic agents |
Country Status (29)
Country | Link |
---|---|
US (2) | US20150086524A1 (xx) |
EP (1) | EP2838566A2 (xx) |
JP (3) | JP2015512927A (xx) |
KR (1) | KR102137290B1 (xx) |
CN (1) | CN104411335A (xx) |
AP (1) | AP2014008049A0 (xx) |
AU (3) | AU2013248296A1 (xx) |
BR (1) | BR112014025737A2 (xx) |
CA (1) | CA2869993C (xx) |
CL (1) | CL2014002773A1 (xx) |
CO (1) | CO7151496A2 (xx) |
CR (1) | CR20140475A (xx) |
EA (1) | EA033469B1 (xx) |
EC (1) | ECSP14023048A (xx) |
GB (3) | GB201910190D0 (xx) |
GE (1) | GEP201706716B (xx) |
HK (1) | HK1200695A1 (xx) |
IL (1) | IL235129B (xx) |
IN (1) | IN2014DN08598A (xx) |
MD (1) | MD20140123A2 (xx) |
MX (2) | MX2014012512A (xx) |
MY (1) | MY190257A (xx) |
NI (1) | NI201400122A (xx) |
NZ (1) | NZ701205A (xx) |
PE (1) | PE20150226A1 (xx) |
PH (1) | PH12014502314A1 (xx) |
SG (1) | SG11201406492YA (xx) |
WO (1) | WO2013156488A2 (xx) |
ZA (1) | ZA201407370B (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109498815B (zh) * | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | 重组人激肽释放酶的化学修饰物及其应用 |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
US20180169297A1 (en) * | 2015-06-12 | 2018-06-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Injectable composition of factor vii and fillers |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
CN109998994B (zh) * | 2018-02-13 | 2021-12-07 | 四川大学 | 包含药物的柔性脂质体及其制备方法 |
CN114929261A (zh) | 2020-02-17 | 2022-08-19 | 生物测试股份公司 | 凝血因子viii的皮下施用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
CH596313A5 (xx) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
WO1990015628A1 (en) * | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
DE69332928T2 (de) | 1992-09-28 | 2004-05-06 | Research Corp. Technologies, Inc., Tucson | Peptidekupplungsreagentien |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
JPH0892294A (ja) * | 1994-09-29 | 1996-04-09 | Teijin Ltd | ヒト活性化プロテインc誘導体 |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
JPH08325270A (ja) * | 1995-05-31 | 1996-12-10 | Bristol Myers Squibb Co | β−ラクタマーゼに対するポリマープロドラッグおよびその使用 |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
EP0921817B1 (en) | 1997-01-29 | 2001-03-28 | PolyMASC Pharmaceuticals plc | Pegylation process |
WO2001082943A2 (en) | 2000-05-03 | 2001-11-08 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor vii |
AU2605099A (en) * | 1998-02-25 | 1999-09-15 | Micrologix Biotech, Inc. | Indolicidin and cationic peptides conjugated with polymers |
ES2325877T3 (es) * | 2000-02-11 | 2009-09-23 | Bayer Healthcare Llc | Moleculas de tipo factor vii o viia. |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
KR101186140B1 (ko) * | 2002-06-21 | 2012-09-27 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 페길화된 인자 vii 글리코형태 |
DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
EP1596887B1 (en) * | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
WO2004089280A2 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
US20130137157A1 (en) * | 2003-04-09 | 2013-05-30 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
JPWO2005084679A1 (ja) | 2004-03-04 | 2007-11-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法 |
MXPA06015234A (es) * | 2004-06-30 | 2007-11-22 | Nektar Therapeutics Al Corp | Conjugados de fraccion polimero-factor ix. |
JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Fviiの抱合体 |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
JP2009515508A (ja) * | 2005-08-19 | 2009-04-16 | ネオス テクノロジーズ インコーポレイテッド | グリコpeg化因子viiおよび因子viia |
AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
ES2521490T3 (es) | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada. |
CN101678119B (zh) * | 2006-12-27 | 2014-02-12 | 尼克塔治疗公司 | 具有可释放的键合的血管性血友病因子-和因子ⅷ-聚合物轭合物 |
EP2099475B1 (en) | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor viia-related polypeptides |
WO2008119815A1 (en) * | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
WO2008127702A2 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
EP2014299A1 (en) | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
JP5733744B2 (ja) | 2007-10-16 | 2015-06-10 | ファーマサイクリックス,インク. | 凝血因子VIIaモジュレーターの製造、組成物及び使用 |
EP2257311B1 (en) | 2008-02-27 | 2014-04-16 | Novo Nordisk A/S | Conjugated factor viii molecules |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
JP2011517950A (ja) * | 2008-04-16 | 2011-06-23 | バイエル・ヘルスケア・エルエルシー | 第ix因子の部位特異的修飾 |
CN102046205A (zh) * | 2008-04-24 | 2011-05-04 | 凯尔特药物Peg有限公司 | 具有延长的半衰期的因子ix缀合物 |
JP5642065B2 (ja) * | 2008-05-23 | 2014-12-17 | ノボ ノルディスク ヘルス ケア アーゲー | ペグ化されたgla−ドメイン含有タンパク質を含む低粘度組成物 |
US8969626B2 (en) | 2008-07-21 | 2015-03-03 | Polytherics Limited | Reagents and method for conjugating biological molecules |
DK2349341T3 (da) * | 2008-10-15 | 2014-01-06 | Baxter Int | Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer |
ES2692172T3 (es) * | 2008-10-17 | 2018-11-30 | Baxalta GmbH | Factores sanguíneos modificados que comprenden un bajo grado de polímero soluble en agua |
WO2010083536A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
WO2011017055A2 (en) * | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
WO2011101242A1 (en) * | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
DK2598172T3 (da) * | 2010-07-30 | 2019-07-01 | Baxalta GmbH | Nukleofile katalysatorer til oximforbindelse |
WO2012088123A1 (en) * | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Polymer-factor vii moiety conjugates |
-
2013
- 2013-04-16 SG SG11201406492YA patent/SG11201406492YA/en unknown
- 2013-04-16 CN CN201380027958.3A patent/CN104411335A/zh active Pending
- 2013-04-16 GB GBGB1910190.6A patent/GB201910190D0/en not_active Ceased
- 2013-04-16 GB GB1418864.3A patent/GB2516388A/en not_active Withdrawn
- 2013-04-16 CA CA2869993A patent/CA2869993C/en active Active
- 2013-04-16 AP AP2014008049A patent/AP2014008049A0/xx unknown
- 2013-04-16 KR KR1020147031042A patent/KR102137290B1/ko active IP Right Grant
- 2013-04-16 NZ NZ701205A patent/NZ701205A/en unknown
- 2013-04-16 GE GEAP201313632A patent/GEP201706716B/en unknown
- 2013-04-16 MY MYPI2014002900A patent/MY190257A/en unknown
- 2013-04-16 IL IL235129A patent/IL235129B/en unknown
- 2013-04-16 AU AU2013248296A patent/AU2013248296A1/en not_active Abandoned
- 2013-04-16 MD MD20140123A patent/MD20140123A2/ro unknown
- 2013-04-16 EA EA201491702A patent/EA033469B1/ru unknown
- 2013-04-16 EP EP13719043.5A patent/EP2838566A2/en active Pending
- 2013-04-16 IN IN8598DEN2014 patent/IN2014DN08598A/en unknown
- 2013-04-16 MX MX2014012512A patent/MX2014012512A/es unknown
- 2013-04-16 BR BR112014025737A patent/BR112014025737A2/pt not_active Application Discontinuation
- 2013-04-16 GB GBGB1910184.9A patent/GB201910184D0/en not_active Ceased
- 2013-04-16 US US14/394,437 patent/US20150086524A1/en not_active Abandoned
- 2013-04-16 WO PCT/EP2013/057928 patent/WO2013156488A2/en active Application Filing
- 2013-04-16 JP JP2015504987A patent/JP2015512927A/ja active Pending
- 2013-04-16 PE PE2014001639A patent/PE20150226A1/es active IP Right Grant
-
2014
- 2014-10-10 ZA ZA2014/07370A patent/ZA201407370B/en unknown
- 2014-10-14 CR CR20140475A patent/CR20140475A/es unknown
- 2014-10-15 NI NI201400122A patent/NI201400122A/es unknown
- 2014-10-15 PH PH12014502314A patent/PH12014502314A1/en unknown
- 2014-10-15 CL CL2014002773A patent/CL2014002773A1/es unknown
- 2014-10-16 MX MX2020014208A patent/MX2020014208A/es unknown
- 2014-10-16 EC ECIEPI201423048A patent/ECSP14023048A/es unknown
- 2014-11-14 CO CO14252826A patent/CO7151496A2/es unknown
-
2015
- 2015-01-27 HK HK15100881.5A patent/HK1200695A1/xx unknown
-
2017
- 2017-08-30 US US15/691,090 patent/US11351112B2/en active Active
- 2017-09-06 JP JP2017171545A patent/JP6550107B2/ja active Active
-
2018
- 2018-01-05 AU AU2018200111A patent/AU2018200111B2/en active Active
-
2019
- 2019-04-05 JP JP2019073048A patent/JP2019131593A/ja active Pending
-
2020
- 2020-02-06 AU AU2020200842A patent/AU2020200842A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203963A1 (en) | Novel therapeutic agents | |
HK1211475A1 (en) | Combination therapy | |
GB201212513D0 (en) | Therapeutic agents | |
ZA201305897B (en) | Combination therapy | |
EP2814472A4 (en) | DITHIOAMINE REDUCING AGENTS | |
GB201114212D0 (en) | Therapeutic agents | |
ZA201400120B (en) | Combination therapy | |
GB201119401D0 (en) | Therapeutic agents | |
EP2740420A4 (en) | THERAPEUTIC TOOL | |
AP2014008049A0 (en) | Optimised subcuraneous therapeutic agents | |
GB201217439D0 (en) | Combination therapy | |
GB201217704D0 (en) | Therapeutic agents | |
GB201207305D0 (en) | Therapy | |
EP2701744A4 (en) | COMBINATION THERAPY | |
HK1210426A1 (en) | Combination therapy | |
EP2688566A4 (en) | ANTICANCER THERAPEUTIC AGENTS | |
EP2804853A4 (en) | THERAPEUTIC USES | |
GB201102913D0 (en) | Novel therapeutic | |
ZA201405764B (en) | Novel therapeutic agents | |
GB201223021D0 (en) | Therapeutic agents | |
GB201212512D0 (en) | Therapeutic agents | |
GB201210233D0 (en) | Therapeutic agents | |
GB201214985D0 (en) | Modified therapeutic agents | |
GB201213712D0 (en) | Modified therapeutic agents | |
IL236873A0 (en) | therapeutic compounds |